Stock fact sheet · data as of
Arbutus Biopharma Corp (ABUS): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Value
Is ABUS undervalued?
ABUS has a margin of safety of 31%: the stock closed at 4.29 on 16 Oct 2026 against a GLS average fair value of 6.25. 3 of the 5 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
There is a wide gap between GLS Growth (2.27) and Graham Growth (12.50). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files ABUS under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for ABUS
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 4.78 | +11% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 12.50 | +191% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 3.10 | -28% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 2.27 | -47% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 8.61 | +101% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.3857 | -91% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 8.50 | +98% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Arbutus Biopharma Corp scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 1.2/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -41.5%, ROE -43.7%, ROA -35.4% - with debt at 0.05 times equity and negative free cash flow.
Arbutus Biopharma Corp pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from License 93%, Service, Other 5%, Non Cash Royalty 2% (quarter Q2 FY2026).
Institutional ownership scores 9/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 18 Sep 2026.
| Piotroski F-score | 5 / 9 | ROIC | -41.5% |
|---|---|---|---|
| GLS Moat | 1.2 / 10 | ROE | -43.7% |
| Debt / equity | 0.05 | ROA | -35.4% |
| Free-cash-flow yield | -2.9% | Payout ratio | 0% |
| Institutions | 9 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 74: Good
With a Wheel Score of 74 - the Good band - Arbutus Biopharma Corp clears the Sunday Scan's "70 or higher" rule. The parts: Value 25/25, Health 11/20, Moat 2/15, Premium 20/20, Stability 16/20; Moat (2/15) scores lowest.
Implied volatility is 54% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. The option chain is deep: 80,051 contracts of open interest across all expiries, which means tight fills at most strikes.
Volume runs at 2.3M shares a day on a market cap of $850M, with a beta of 0.62 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 16 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 31% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 2 / 15 | moat 1.2/10 | |
| Premium | 20 / 20 | implied volatility 54% | |
| Stability | 16 / 20 | 2.3M shares/day, $850M cap, beta 0.62 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 16 Nov 2026, 31 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Arbutus Biopharma Corp by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ODTX Odyssey Therapeutics, Inc. | 17.57 | - | - | 24No options | $844M |
| CGEM Cullinan Therapeutics, Inc. | 14.00 | 1.44 | -874% | 22Weak | $860M |
| AKTS Aktis Oncology, Inc. | 16.01 | 2.99 | -436% | 28Weak | $860M |
| KURA Kura Oncology, Inc. | 9.70 | 16.14 | +40% | 45Weak | $863M |
| GLUE Monte Rosa Therapeutics, Inc. | 10.12 | 33.55 | +70% | 45Weak | $863M |
| SLBT SL Science Holding Ltd | 1.55 | - | - | 25No options | $869M |
| CRVS Corvus Pharmaceuticals, Inc. | 9.85 | 0.0213 | -46156% | 34Weak | $829M |
| AVBP ArriVent BioPharma, Inc. | 16.79 | 1.05 | -1504% | 27Weak | $828M |
| MLTX MoonLake Immunotherapeutics | 10.26 | 4.08 | -151% | 31Weak | $873M |
| RIGL Rigel Pharmaceuticals, Inc. | 46.82 | 408.96 | +89% | 64Fair | $875M |
| JBIO Jade Biosciences, Inc. | 13.76 | 2.74 | -403% | 32Weak | $875M |
| ALMS Alumis Inc. | 6.31 | 0.8880 | -611% | 37Weak | $817M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ABUS
Is ABUS undervalued right now?
By the GLS models, yes: at 4.29 the stock is 31% below the average fair value of 6.25 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ABUS and what does it mean?
ABUS scores 74 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for ABUS?
6.25 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Arbutus Biopharma Corp report earnings next?
The next earnings report is due on 16 Nov 2026, 31 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ABUS have listed options, and how liquid are they?
Yes. The nightly snapshot found 114 listed contracts with 80,051 open interest across all expiries and implied volatility of 54% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.